Cargando…

Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease

BACKGROUND: Minimal change disease is a common cause of nephrotic syndrome in adults. Higher relapse rate put patients at risk of steroids toxicity due to long-term exposure. Rituximab has been suggested to maintain long time remission and withdraw steroids and other immunosuppressants with fewer ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Diankun, Zhou, Zhanmei, Wang, Mengyi, Nie, Sheng, Li, Jun, Hu, Bianxiang, He, Wenjuan, Wang, Guobao, Ai, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247102/ https://www.ncbi.nlm.nih.gov/pubmed/34210283 http://dx.doi.org/10.1186/s12882-021-02437-4

Ejemplares similares

Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease
por: Papakrivopoulou, Eugenia, et al.
Publicado: (2016)

Sustained complete remission of steroid- and cyclophosphamide-resistant minimal-change disease with a single course of rituximab therapy
por: Janardan, Jyotsna, et al.
Publicado: (2014)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

The efficacy of rituximab in adult frequently relapsing minimal change disease
por: King, Catherine, et al.
Publicado: (2017)

RELAPSE AND REMITTING COVID-19 INFECTIONS IN AN IMMUNOSUPPRESSED PATIENT ON CHRONIC RITUXIMAB INFUSIONS
por: GREWAL, SAHIB, et al.
Publicado: (2021)

Rituximab therapy in adults with steroid-dependent nephrotic syndrome
por: Zhong, Hongzhen, et al.
Publicado: (2019)

Efficacy of low-dose rituximab in minimal change disease and prevention of relapse
por: Zhang, Jian, et al.
Publicado: (2023)

Nephron Number and Time to Remission in Steroid-Sensitive Minimal Change Disease
por: Sasaki, Takaya, et al.
Publicado: (2020)

Systematic Review and Meta-Analysis of Rituximab for Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome in Children
por: Gao, Xia, et al.
Publicado: (2021)

Rituximab for Steroid-Dependent Minimal Change Disease in Adults: Is It Time for a Change?
por: Kannan, Lakshmi
Publicado: (2022)

Comparison of the response of frequently relapsing steroid-dependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease
por: Iwabuchi, Yuko, et al.
Publicado: (2018)

Population Pharmacokinetics of Rituximab in Pediatric Patients With Frequent-Relapsing or Steroid-Dependent Nephrotic Syndrome
por: Chen, Yewei, et al.
Publicado: (2021)

Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis
por: Xue, Cheng, et al.
Publicado: (2020)

Rituximab Induces Complete Remission of Proteinuria in a Patient With Minimal Change Disease and No Detectable B Cells
por: Webendörfer, Maximilian, et al.
Publicado: (2021)

DNA methylation changes between relapse and remission of minimal change nephrotic syndrome
por: Kobayashi, Yasuko, et al.
Publicado: (2012)

Rituximab, Mycophenolic Acid, and Calcineurin Inhibitors Achieve Long-Term Remission in Pediatric Focal Segmental Glomerulosclerosis with Steroid-Resistant and Frequently Relapsing Nephrotic Syndrome: A Report of Two Cases
por: Ambarsari, Cahyani Gita, et al.
Publicado: (2022)

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021)

SEVERE ADENOVIRUS PNEUMONIA IN RITUXIMAB INFUSIONS
por: BJORK, SARAH, et al.
Publicado: (2021)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
por: Smith, Rona M, et al.
Publicado: (2023)

Comparison of rituximab, cyclophosphamide, and tacrolimus as first steroid-sparing agents for complicated relapsing/steroid-dependent nephrotic syndrome in children: an evaluation of the health-related quality of life
por: Wang, Li, et al.
Publicado: (2022)

Induction of Remission is Difficult due to Frequent Relapse during Tapering Steroids in Korean Patients with Polymyalgia Rheumatica
por: Kim, Hyoun-Ah, et al.
Publicado: (2012)

Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?
por: Patel, Jolly, et al.
Publicado: (2013)

Allergic/infusion reactions reported with cetuximab and rituximab
por: Wolf, Ray A, et al.
Publicado: (2015)

IgM deposition is a risk factor for delayed remission and early relapse of the pediatric minimal change disease
por: Ju, Tao, et al.
Publicado: (2023)

Minimal Change Nephrotic Syndrome Relapse after 52 Years of Remission: A Case Report
por: Yamabe, Hideaki, et al.
Publicado: (2018)

Remissions and Relapses in Insular Sclerosis
Publicado: (1904)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

Long-Term Prognosis of Adult Patients with Steroid-Dependent Minimal Change Nephrotic Syndrome Following Rituximab Treatment
por: Iwabuchi, Yuko, et al.
Publicado: (2014)

Long-term Successful Treatment of Rituximab for Steroid-resistant Minimal Change Nephrotic Syndrome and Idiopathic Thrombocytopenic Purpura
por: Nishikawa, Mana, et al.
Publicado: (2019)

Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias
por: Nikitin, Eugene, et al.
Publicado: (2023)

Wegener's Granulomatosis Presenting with Pachymeningitis: Clinical and Imaging Remission by Rituximab
por: Just, Søren Andreas, et al.
Publicado: (2011)

Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
por: Bonilla-Abadía, Fabio, et al.
Publicado: (2014)

Remission Achieved in Refractory Advanced Takayasu Arteritis Using Rituximab
por: Ernst, D., et al.
Publicado: (2012)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
por: Cortazar, Frank B., et al.
Publicado: (2017)

Rituximab-Induced Remission in Epstein−Barr Virus−Associated Glomerulonephritis
por: Alabdaljabar, Mohamad S., et al.
Publicado: (2020)

Acute Respiratory Distress Syndrome after Rituximab Infusion
por: Montero, Alberto J., et al.
Publicado: (2005)

Association of initial prednisolone dose with remission, relapse, and infectious complications in adult-onset minimal change disease
por: Tanabe, Kaori, et al.
Publicado: (2021)

Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial
por: Hogan, Julien, et al.
Publicado: (2020)

Remission of Refractory Membranous Nephropathy by Low-dose Rituximab: A Case Report
por: Wang, Xiao-Pei, et al.
Publicado: (2016)

3D hypoxia-mimicking and anti-synechia hydrogel enabling promoted neovascularization for renal injury repair and regeneration
por: Zhang, Yuehang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3jol42aatohd33snu1obo0mq7e